CARL TAHN
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology ROCKLEDGE, FL NPI 1508961319
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology FL TAIHO ONCOLOGY, INC. All categories
General Payments — all program years on this page
$17,068.90
- Category: General Payments
- Program years: PY2018–2024
- Record count: 351
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $3,654.16 across 67 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,450.00 | 3 |
| Food and Beverage | $1,204.16 | 64 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| TAIHO ONCOLOGY, INC. | $1,400.00 | 1 |
| Acerta Pharma LLC | $1,186.73 | 10 |
| Merck Sharp & Dohme Corporation | $143.95 | 8 |
| ABBVIE INC. | $105.58 | 4 |
| PFIZER INC. | $90.02 | 5 |
| GENZYME CORPORATION | $56.81 | 3 |
| EMD Serono, Inc. | $54.00 | 3 |
| Genentech USA, Inc. | $45.76 | 3 |
| Tempus AI, Inc | $44.51 | 2 |
| Janssen Biotech, Inc. | $43.52 | 2 |
| Lilly USA, LLC | $43.32 | 2 |
| Genmab U.S., Inc. | $43.18 | 2 |
| GlaxoSmithKline, LLC. | $37.63 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $36.08 | 2 |
| EISAI INC. | $32.90 | 2 |
| Daiichi Sankyo Inc. | $29.92 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.11 | 1 |
| TerSera Therapeutics LLC | $27.52 | 1 |
| SOBI, INC | $23.41 | 1 |
| Myriad Genetic Laboratories, Inc. | $21.87 | 1 |
| AVEO Pharmaceuticals, Inc. | $19.70 | 1 |
| Regeneron Healthcare Solutions, Inc. | $18.09 | 1 |
| Astellas Pharma US Inc | $18.03 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.86 | 1 |
| Stemline Therapeutics Inc. | $15.98 | 1 |
| Gilead Sciences, Inc. | $15.03 | 1 |
| Exelixis Inc. | $14.27 | 1 |
| ImmunoGen, Inc. | $13.75 | 1 |
| TOLMAR, INC. | $13.34 | 1 |
| Incyte Corporation | $13.29 | 1 |
By program year
Records — PY2024 (67)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.